


Pharmaceuticals & Biotechnology | Small Cap
Kopran Ltd, operating within the Healthcare Services sector, exhibits a mixed financial profile. The company demonstrates very strong solvency and growth, indicating a solid foundation and expansion. Profitability is also a notable strength, reflecting efficient operations and good returns. However, efficiency and financial ratios reveal areas needing attention. Liquidity is average, suggesting moderate short-term financial health. Overall, Kopran Ltd showcases robust growth and profitability, but could benefit from improvements in operational efficiency and financial management to achieve a more balanced and stronger financial standing. While showing good potential, the company's inconsistent financial metrics suggest the need for strategic adjustments to ensure sustained success.
Kopran Ltd, operating within the Healthcare Services sector, exhibits a mixed financial profile. The company demonstrates very strong solvency and growth, indicating a solid foundation and expansion. Profitability is also a notable strength, reflecting efficient operations and good returns. However, efficiency and financial ratios reveal areas needing attention. Liquidity is average, suggesting moderate short-term financial health. Overall, Kopran Ltd showcases robust growth and profitability, but could benefit from improvements in operational efficiency and financial management to achieve a more balanced and stronger financial standing. While showing good potential, the company's inconsistent financial metrics suggest the need for strategic adjustments to ensure sustained success.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
56.51
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
25.82
P/B RATIO
1.98
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
1.58
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
2.08
EV/EBITDA RATIO
12.63
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹206.27 as on Jun 15, 2026.
The company showcases very strong growth across all metrics. High revenue growth, operating profit growth, EPS growth, asset growth, and net income growth indicate robust expansion and market performance. This suggests effective strategies and strong market positioning. The healthcare industry benefits from consistent growth to meet increasing demand.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -2.85 | 15.27 | 11.62 | 2.44 | 8.1 |
| Operating Profit Growth Rate | 6.1 | -40.23 | 42.31 | -1.35 | -15.07 |
| Earnings Per Share (EPS) Growth | -11.1 | -55.37 | 87.08 | -24.41 | -33.29 |
| Asset Growth Rate | 39.18 | 6.38 | 14.31 | 13.59 | 7.58 |
| Net Income Growth Rate | -1.61 | -55.74 | 88.89 | -23.53 | -33.33 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.81 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 4 | NGL Fine Chem Ltd | 6.98 | 44.01 | Overvalued | 73.00 | 67.39 | 48.00 |
| 5 | Sakar Healthcare Ltd | 6.89 | 67.13 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 6 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 7 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 8 | SMS Lifesciences India Ltd | 6.59 | 21.63 | Undervalued | 45.00 | 58.80 | 19.00 |
| 9 | Infinium Pharmachem Ltd | 6.42 | 26.92 | Neutral | 22.00 | 6.43 | 14.00 |
| 10 | Medicamen Biotech Ltd | 5.73 | 33.43 | Neutral | 20.00 | 6.94 | 10.00 |
| 11 | Albert David Ltd | 5.63 | -279.90 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | BPL Ltd | 5.46 | -30.53 | Neutral | -4.82 | -1.69 | -8.55 |
| 13 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 14 | Remus Pharmaceuticals Ltd | 5.31 | 25.82 | Neutral | 57.00 | 20.97 | 46.00 |
| 15 | Ind-Swift Laboratories Ltd | 4.95 | 47.48 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 17 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 18 | Wanbury Ltd | 4.65 | 29.43 | Neutral | 88.00 | 18.93 | 43.00 |
| 19 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Quarterly Report⬤22nd Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT